Cyrille Hoarau
François Rabelais University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Cyrille Hoarau.
Journal of Experimental Medicine | 2008
Ludovic de Beaucoudrey; Anne Puel; Aurélie Cobat; Pegah Ghandil; Maya Chrabieh; Jacqueline Feinberg; Horst von Bernuth; Arina Samarina; Lucile Jannière; Claire Fieschi; Jean-Louis Stephan; Catherine Boileau; Stanislas Lyonnet; Guillaume Jondeau; Valérie Cormier-Daire; Martine Le Merrer; Cyrille Hoarau; Yvon Lebranchu; Olivier Lortholary; Marie-Olivia Chandesris; François Tron; Eleonora Gambineri; Lucia Bianchi; Carlos Rodríguez-Gallego; Simona Eva Zitnik; Júlia Vasconcelos; Margarida Guedes; Artur Bonito Vitor; László Maródi; Helen Chapel
The cytokines controlling the development of human interleukin (IL) 17–producing T helper cells in vitro have been difficult to identify. We addressed the question of the development of human IL-17–producing T helper cells in vivo by quantifying the production and secretion of IL-17 by fresh T cells ex vivo, and by T cell blasts expanded in vitro from patients with particular genetic traits affecting transforming growth factor (TGF) β, IL-1, IL-6, or IL-23 responses. Activating mutations in TGFB1, TGFBR1, and TGFBR2 (Camurati-Engelmann disease and Marfan-like syndromes) and loss-of-function mutations in IRAK4 and MYD88 (Mendelian predisposition to pyogenic bacterial infections) had no detectable impact. In contrast, dominant-negative mutations in STAT3 (autosomal-dominant hyperimmunoglobulin E syndrome) and, to a lesser extent, null mutations in IL12B and IL12RB1 (Mendelian susceptibility to mycobacterial diseases) impaired the development of IL-17–producing T cells. These data suggest that IL-12Rβ1– and STAT-3–dependent signals play a key role in the differentiation and/or expansion of human IL-17–producing T cell populations in vivo.
Medicine | 2010
Capucine Picard; Horst von Bernuth; Pegah Ghandil; Maya Chrabieh; Ofer Levy; Peter D. Arkwright; Douglas R. McDonald; Raif S. Geha; Hidetoshi Takada; Jens Krause; C. Buddy Creech; Cheng Lung Ku; Stephan Ehl; László Maródi; Saleh Al-Muhsen; Sami Al-Hajjar; Abdulaziz Al-Ghonaium; Noorbibi K. Day-Good; Steven M. Holland; John I. Gallin; Helen Chapel; David P. Speert; Carlos Rodríguez-Gallego; Elena Colino; Ben Zion Garty; Chaim Roifman; Toshiro Hara; Hideto Yoshikawa; Shigeaki Nonoyama; Joseph B. Domachowske
Autosomal recessive interleukin-1 receptor-associated kinase (IRAK)-4 and myeloid differentiation factor (MyD)88 deficiencies impair Toll-like receptor (TLR)- and interleukin-1 receptor-mediated immunity. We documented the clinical features and outcome of 48 patients with IRAK-4 deficiency and 12 patients with MyD88 deficiency, from 37 kindreds in 15 countries. The clinical features of IRAK-4 and MyD88 deficiency were indistinguishable. There were no severe viral, parasitic, and fungal diseases, and the range of bacterial infections was narrow. Noninvasive bacterial infections occurred in 52 patients, with a high incidence of infections of the upper respiratory tract and the skin, mostly caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively. The leading threat was invasive pneumococcal disease, documented in 41 patients (68%) and causing 72 documented invasive infections (52.2%). P. aeruginosa and Staph. aureus documented invasive infections also occurred (16.7% and 16%, respectively, in 13 and 13 patients, respectively). Systemic signs of inflammation were usually weak or delayed. The first invasive infection occurred before the age of 2 years in 53 (88.3%) and in the neonatal period in 19 (32.7%) patients. Multiple or recurrent invasive infections were observed in most survivors (n = 36/50, 72%). Clinical outcome was poor, with 24 deaths, in 10 cases during the first invasive episode and in 16 cases of invasive pneumococcal disease. However, no death and invasive infectious disease were reported in patients after the age of 8 years and 14 years, respectively. Antibiotic prophylaxis (n = 34), antipneumococcal vaccination (n = 31), and/or IgG infusion (n = 19), when instituted, had a beneficial impact on patients until the teenage years, with no seemingly detectable impact thereafter. IRAK-4 and MyD88 deficiencies predispose patients to recurrent life-threatening bacterial diseases, such as invasive pneumococcal disease in particular, in infancy and early childhood, with weak signs of inflammation. Patients and families should be informed of the risk of developing life-threatening infections; empiric antibacterial treatment and immediate medical consultation are strongly recommended in cases of suspected infection or moderate fever. Prophylactic measures in childhood are beneficial, until spontaneous improvement occurs in adolescence. Abbreviations: CRP = C-reactive protein, ELISA = enzyme-linked immunosorbent assay, IFN = interferon, IKBA = I&kgr;B&agr;, IL = interleukin, IL-1R = interleukin-1 receptor, InvBD = invasive bacterial disease, IRAK = interleukin-1 receptor-associated kinase, MyD = myeloid differentiation factor, NEMO = nuclear factor-kappaB essential modulator, NInvBD = noninvasive bacterial disease, TIR = Toll/IL-1R, TLR = Toll-like receptor, TNF = tumor necrosis factor.
Blood | 2012
Sandra K. Weller; Mélanie Bonnet; Héloïse Delagreverie; Laura Israel; Maya Chrabieh; László Maródi; Carlos Rodríguez-Gallego; Ben Zion Garty; Chaim Roifman; Andrew C. Issekutz; Simona Eva Zitnik; Cyrille Hoarau; Yildiz Camcioglu; Júlia Vasconcelos; Carlos Rodrigo; Peter D. Arkwright; Andrea Cerutti; Eric Meffre; Shen-Ying Zhang; Alexandre Alcaïs; Anne Puel; Jean-Laurent Casanova; Capucine Picard; Jean Claude Weill; Claude Agnès Reynaud
We studied the distribution of peripheral B-cell subsets in patients deficient for key factors of the TLR-signaling pathways (MyD88, TIRAP/MAL, IL-1 receptor-associated kinase 4 [IRAK-4], TLR3, UNC-93B, TRIF). All TLRs, except TLR3, which signals through the TRIF adaptor, require MyD88 and IRAK-4 to mediate their function. TLR4 and the TLR2 heterodimers (with TLR1, TLR6, and possibly TLR10) require in addition the adaptor TIRAP, whereas UNC-93B is needed for the proper localization of intracellular TLR3, TLR7, TLR8, and TLR9. We found that IgM(+)IgD(+)CD27(+) but not switched B cells were strongly reduced in MyD88-, IRAK-4-, and TIRAP-deficient patients. This defect did not appear to be compensated with age. However, somatic hypermutation of Ig genes and heavy-chain CDR3 size distribution of IgM(+)IgD(+)CD27(+) B cells were not affected in these patients. In contrast, the numbers of IgM(+)IgD(+)CD27(+) B cells were normal in the absence of TLR3, TRIF, and UNC-93B, suggesting that UNC-93B-dependent TLRs, and notably TLR9, are dispensable for the presence of this subset in peripheral blood. Interestingly, TLR10 was found to be expressed at greater levels in IgM(+)IgD(+)CD27(+) compared with switched B cells in healthy patients. Hence, we propose a role for TIRAP-dependent TLRs, possibly TLR10 in particular, in the development and/or maintenance of IgM(+)IgD(+)CD27(+) B cells in humans.
PLOS ONE | 2008
Cyrille Hoarau; Laurence Martin; Delphine Faugaret; Christophe Baron; Audrey Dauba; Cécile Aubert-Jacquin; Florence Velge-Roussel; Yvon Lebranchu
Background Probiotic bacteria have been shown to modulate immune responses and could have therapeutic effects in allergic and inflammatory disorders. However, the signaling pathways engaged by probiotics are poorly understood. We have previously reported that a fermentation product from Bifidobacterium breve C50 (BbC50sn) could induce maturation, high IL-10 production and prolonged survival of DCs via a TLR2 pathway. We therefore studied the roles of mitogen-activated protein kinases (MAPK), glycogen synthase kinase-3 (GSK3) and phosphatidylinositol 3-kinase (PI3K) pathways on biological functions of human monocyte-derived DCs treated with BbC50sn. Methodology/Principal Findings DCs were differentiated from human monocytes with IL-4 and GM-CSF for 5 days and cultured with BbC50sn, lipopolysaccharide (LPS) or Zymosan, with or without specific inhibitors of p38MAPK (SB203580), ERK (PD98059), PI3K (LY294002) and GSK3 (SB216763). We found that 1) the PI3K pathway was positively involved in the prolonged DC survival induced by BbC50sn, LPS and Zymosan in contrast to p38MAPK and GSK3 which negatively regulated DC survival; 2) p38MAPK and PI3K were positively involved in DC maturation, in contrast to ERK and GSK3 which negatively regulated DC maturation; 3) ERK and PI3K were positively involved in DC-IL-10 production, in contrast to GSK3 that was positively involved in DC-IL-12 production whereas p38MAPK was positively involved in both; 4) BbC50sn induced a PI3K/Akt phosphorylation similar to Zymosan and a p38MAPK phosphorylation similar to LPS. Conclusion/Significance We report for the first time that a fermentation product of a bifidobacteria can differentially activate MAPK, GSK3 and PI3K in order to modulate DC biological functions. These results give new insights on the fine-tuned balance between the maintenance of normal mucosal homeostasis to commensal and probiotic bacteria and the specific inflammatory immune responses to pathogen bacteria.
Journal of Immunology | 2007
Cyrille Hoarau; Bénédicte Gérard; Emmanuel Lescanne; Dominique Henry; Stéphanie François; Jean-Jacques Lacapère; Jamel El Benna; Pham My-Chan Dang; Bernard Grandchamp; Yvon Lebranchu; Marie-Anne Gougerot-Pocidalo; Carole Elbim
Polymorphonuclear neutrophils (PMN) play a key role in innate immunity. Their activation and survival are tightly regulated by microbial products via pattern recognition receptors such as TLRs, which mediate recruitment of the IL-1R-associated kinase (IRAK) complex. We describe a new inherited IRAK-4 deficiency in a child with recurrent pyogenic bacterial infections. Analysis of the IRAK4 gene showed compound heterozygosity with two mutations: a missense mutation in the death domain of the protein (pArg12Cys) associated in cis-with a predicted benign variant (pArg391His); and a splice site mutation in intron 7 that led to the skipping of exon 7. A nontruncated IRAK-4 protein was detected by Western blotting. The patient’s functional deficiency of IRAK-4 protein was confirmed by the absence of IRAK-1 phosphorylation after stimulation with all TLR agonists tested. The patient’s PMNs showed strongly impaired responses (L-selectin and CD11b expression, oxidative burst, cytokine production, cell survival) to TLR agonists which engage TLR1/2, TLR2/6, TLR4, and TLR7/8; in contrast, the patient’s PMN responses to CpG-DNA (TLR9) were normal, except for cytokine production. The surprisingly normal effect of CpG-DNA on PMN functions and apoptosis disappeared after pretreatment with PI3K inhibitors. Together, these results suggest the existence of an IRAK-4-independent TLR9-induced transduction pathway leading to PI3K activation. This alternative pathway may play a key role in PMN control of infections by microorganisms other than pyogenic bacteria in inherited IRAK-4 deficiency.
Circulation-cardiovascular Genetics | 2012
Marie-Olivia Chandesris; Arshid Azarine; Kim-Thanh Ong; Soraya Taleb; Pierre Boutouyrie; Elie Mousseaux; Mélissa Romain; Erwan Bozec; Stéphane Laurent; Nathalie Boddaert; C. Thumerelle; Isabelle Tillie-Leblond; Cyrille Hoarau; Yvon Lebranchu; Nathalie Aladjidi; François Tron; Vincent Barlogis; Gérard Body; Marine Munzer; Roland Jaussaud; Felipe Suarez; Olivier Clément; Olivier Hermine; Alain Tedgui; Olivier Lortholary; Capucine Picard; Ziad Mallat; Alain Fischer
Background —STAT3 deficiency is responsible for autosomal dominant hyper-IgE syndrome characterized by recurrent bacterial and fungal infections, connective tissue abnormalities, hyper-IgE and Th17 lymphopenia. Although vascular abnormalities have been reported in some patients, the prevalence, characteristics and etiology of these features have yet to be described. Methods and Results —We prospectively screened 21 adult STAT3-deficient patients (median age: 26 years; range 17 - 44) for vascular abnormalities. They were explored with whole-body magnetic resonance imaging angiography, coronary multislice computed tomography and echo-tracking-based imaging of the carotid arteries. We also assayed for serum biomarkers of inflammation and endothelial dysfunction. Finally, murine models of aortic aneurysm were studied in the presence and absence of inhibitors of STAT3-dependent signaling. Brain abnormalities (white matter hyperintensities, lacunar lesions suggestive of ischemic infarcts, atrophy) were found in 95% of patients. Peripheral and brain artery abnormalities were reported in 84% of patients, whereas coronary artery abnormalities were detected in 50%. The most frequent vascular abnormalities were ectasia and aneurysm. The carotid intima-media thickness was markedly decreased, with a substantial increase in circumferential wall stress indicating the occurrence of hypotrophic arterial remodeling in this STAT3-deficient population. Systemic inflammatory biomarker levels correlated poorly with the vascular phenotype. In vivo inhibition of STAT3 signaling or blockade of IL-17A resulted in a marked increase in aneurysm severity and fatal rupture in mouse models. Conclusions —Vascular abnormalities are highly prevalent in STAT3-deficient patients. This feature is consistent with the greater susceptibility to vascular aneurysm observed after inhibition of STAT3-dependent signaling in mouse models.Background— Signal transducer and activator of transcription 3 (STAT3) deficiency is responsible for autosomal dominant hyperimmunoglobulin E syndrome, characterized by recurrent bacterial and fungal infections, connective tissue abnormalities, hyperimmunoglobulin E, and Th17 lymphopenia. Although vascular abnormalities have been reported in some patients, the prevalence, characteristics, and etiology of these features have yet to be described. Methods and Results— We prospectively screened 21 adult patients with STAT3 deficiency (median age, 26 years; range, 17 to 44) for vascular abnormalities. We explored the carotid arteries with whole-body magnetic resonance imaging angiography, coronary multislice computed tomography, and echo-tracking–based imaging. We also assayed for serum biomarkers of inflammation and endothelial dysfunction. Finally, we studied murine models of aortic aneurysm in the presence and absence of inhibitors of STAT3-dependent signaling. Ninety-five percent of patients showed brain abnormalities (white matter hyperintensities, lacunar lesions suggestive of ischemic infarcts, and atrophy). We reported peripheral and brain artery abnormalities in 84% of the patients and detected coronary artery abnormalities in 50% of the patients. The most frequent vascular abnormalities were ectasia and aneurysm. The carotid intima-media thickness was markedly decreased, with a substantial increase in circumferential wall stress, indicating the occurrence of hypotrophic arterial remodeling in this STAT3-deficient population. Systemic inflammatory biomarker levels correlated poorly with the vascular phenotype. In vivo inhibition of STAT3 signaling or blockade of IL-17A resulted in a marked increase in aneurysm severity and fatal rupture in mouse models. Conclusions— Vascular abnormalities are highly prevalent in patients with STAT3 deficiency. This feature is consistent with the greater susceptibility to vascular aneurysm observed after inhibition of STAT3-dependent signaling in mouse models.
Circulation-cardiovascular Genetics | 2011
Marie-Olivia Chandesris; Arshid Azarine; Kim-Thanh Ong; Soraya Taleb; Pierre Boutouyrie; Elie Mousseaux; Mélissa Romain; Erwan Bozec; Stéphane Laurent; Nathalie Boddaert; Caroline Thumerelle; Isabelle Tillie-Leblond; Cyrille Hoarau; Yvon Lebranchu; Nathalie Aladjidi; François Tron; Vincent Barlogis; Gérard Body; Marine Munzer; Roland Jaussaud; Felipe Suarez; Olivier Clément; Olivier Hermine; Alain Tedgui; Olivier Lortholary; Capucine Picard; Ziad Mallat; Alain Fischer
Background —STAT3 deficiency is responsible for autosomal dominant hyper-IgE syndrome characterized by recurrent bacterial and fungal infections, connective tissue abnormalities, hyper-IgE and Th17 lymphopenia. Although vascular abnormalities have been reported in some patients, the prevalence, characteristics and etiology of these features have yet to be described. Methods and Results —We prospectively screened 21 adult STAT3-deficient patients (median age: 26 years; range 17 - 44) for vascular abnormalities. They were explored with whole-body magnetic resonance imaging angiography, coronary multislice computed tomography and echo-tracking-based imaging of the carotid arteries. We also assayed for serum biomarkers of inflammation and endothelial dysfunction. Finally, murine models of aortic aneurysm were studied in the presence and absence of inhibitors of STAT3-dependent signaling. Brain abnormalities (white matter hyperintensities, lacunar lesions suggestive of ischemic infarcts, atrophy) were found in 95% of patients. Peripheral and brain artery abnormalities were reported in 84% of patients, whereas coronary artery abnormalities were detected in 50%. The most frequent vascular abnormalities were ectasia and aneurysm. The carotid intima-media thickness was markedly decreased, with a substantial increase in circumferential wall stress indicating the occurrence of hypotrophic arterial remodeling in this STAT3-deficient population. Systemic inflammatory biomarker levels correlated poorly with the vascular phenotype. In vivo inhibition of STAT3 signaling or blockade of IL-17A resulted in a marked increase in aneurysm severity and fatal rupture in mouse models. Conclusions —Vascular abnormalities are highly prevalent in STAT3-deficient patients. This feature is consistent with the greater susceptibility to vascular aneurysm observed after inhibition of STAT3-dependent signaling in mouse models.Background— Signal transducer and activator of transcription 3 (STAT3) deficiency is responsible for autosomal dominant hyperimmunoglobulin E syndrome, characterized by recurrent bacterial and fungal infections, connective tissue abnormalities, hyperimmunoglobulin E, and Th17 lymphopenia. Although vascular abnormalities have been reported in some patients, the prevalence, characteristics, and etiology of these features have yet to be described. Methods and Results— We prospectively screened 21 adult patients with STAT3 deficiency (median age, 26 years; range, 17 to 44) for vascular abnormalities. We explored the carotid arteries with whole-body magnetic resonance imaging angiography, coronary multislice computed tomography, and echo-tracking–based imaging. We also assayed for serum biomarkers of inflammation and endothelial dysfunction. Finally, we studied murine models of aortic aneurysm in the presence and absence of inhibitors of STAT3-dependent signaling. Ninety-five percent of patients showed brain abnormalities (white matter hyperintensities, lacunar lesions suggestive of ischemic infarcts, and atrophy). We reported peripheral and brain artery abnormalities in 84% of the patients and detected coronary artery abnormalities in 50% of the patients. The most frequent vascular abnormalities were ectasia and aneurysm. The carotid intima-media thickness was markedly decreased, with a substantial increase in circumferential wall stress, indicating the occurrence of hypotrophic arterial remodeling in this STAT3-deficient population. Systemic inflammatory biomarker levels correlated poorly with the vascular phenotype. In vivo inhibition of STAT3 signaling or blockade of IL-17A resulted in a marked increase in aneurysm severity and fatal rupture in mouse models. Conclusions— Vascular abnormalities are highly prevalent in patients with STAT3 deficiency. This feature is consistent with the greater susceptibility to vascular aneurysm observed after inhibition of STAT3-dependent signaling in mouse models.
Journal of Clinical Immunology | 2012
Claire Rivoisy; Laurence Gérard; David Boutboul; Marion Malphettes; Claire Fieschi; I. Durieu; François Tron; Agathe Masseau; Pierre Bordigoni; Laurent Alric; Julien Haroche; Cyrille Hoarau; Alice Bérezné; Maryvonnick Carmagnat; Gaël Mouillot; Eric Oksenhendler
The DEFI study has collected clinical data and biological specimens from kindreds with CVID. Patients with demonstrated parental consanguinity (cCVID group) were compared to patients without parental consanguinity (ncCVID). A total of 24 of the 436 patients with CVID had consanguineous parents. Age at first symptoms and age at diagnosis were comparable in the two groups. Some complications were more frequent in cCVID patients: splenomegaly (62.5% vs. 29%; p = 0.001), granulomatous disease (29% vs. 12%; p = 0.02), and bronchiectasis (58% vs. 29%; p = 0.003). A high incidence of opportunistic infections was also observed in this population (29% vs. 5%; p < 0.001). Distribution of B-cell subsets were similar in the two groups. Naïve CD4+ T cells were decreased in cCVID patients (15% vs. 28%; p < 0.001), while activated CD4 + CD95+ (88% vs. 74%; p = 0.002) and CD8 + HLA-DR + T cells (47% vs. 31%; p < 0.001) were increased in these patients when compared to ncCVID patients. Parental consanguinity is associated with an increased risk of developing severe clinical complications in patients with CVID. Most of these patients presented with severe T-cell abnormalities and should be considered with a diagnosis of late-onset combined immune deficiency (LOCID). Systematic investigation for parental consanguinity in patients with CVID provides useful information for specific clinical care and genetic screening.
mAbs | 2011
Florence Uettwiller; Émilie Rigal; Cyrille Hoarau
Monoclonal antibodies (mAbs), especially those that interact with immune or hematologic leukocyte membrane targets, have changed the outcome of numerous diseases. However, mAbs can block or reduce immune cells and cytokines, and can lead to increased risk of infection. Some of these risks are predictable and can be explained by their mechanisms of action. Others have been observed only after the mAbs were licensed and used extensively in patients. In this review, we focus on infectious complications that occur upon treatment with mAbs or Fc-containing fusion proteins targeting leukocyte membrane proteins, including CD52, CD20, tumor necrosis factor, VLA4, CD11a and CTLA4. We report their known infectious risks and the recommendations for their use. Although most of these drugs are clinically safe when the indications are respected, we emphasize the need for regular updating of pharmacovigilance data.
Transplant Immunology | 2002
Sandrine Cappellesso; Gilles Thibault; Cyrille Hoarau; Olivier Herault; Sophie Iochmann; Pierre Bardos; Yvon Lebranchu
Graft endothelium has a key role in organ transplantation because it regulates graft infiltration by allogeneic activated T cells. Overexpression of death molecules that could induce apoptosis of alloreactive T cells might be an alternative to the immunosuppressive treatment currently used in graft transplantation. Several studies have shown that immune-privileged sites express Fas ligand (FasL) and induce apoptosis of activated T-cells. We propose that endothelial cells engineered to express FasL could inhibit alloreactive T cell-proliferation by inducing apoptosis. An expression vector was constructed with human FasL cDNA and used to transfect an endothelial cell line (ECV304 cells). We demonstrated that FasL-transfected ECV304 cells were effective in inducing apoptosis of Jurkat T cell lymphoma as an agonist anti-Fas antibody. Using a mixed lymphocyte-endothelial cell culture model we observed that FasL-transfected ECV304 cells which conserved their two principal costimulatory pathways inhibited alloreactive T cell-proliferation by inducing activated T-cell apoptosis. These results suggest that endothelial cells could be interesting candidates to convey a death signal and induce hyporesponsiveness of alloreactive T cells during organ transplantation.